Skip to content

Elite Pharmaceuticals, Inc.: 10-Q filed 2021-02-16

What Elite Pharmaceuticals, Inc. reported in its quarterly report filed 2021-02-16 (fiscal Q3 2021): 48 published measures, 141 facts as tagged in accession 0001213900-21-009615.

This filing

Form
10-Q (quarterly report)
Filed
2021-02-16
Fiscal period
fiscal Q3 2021
Accession
0001213900-21-009615 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Elite Pharmaceuticals, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2020-12-3128,665,237USD
At 2020-03-3124,956,580USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2020-12-3112,034,605USD
At 2020-03-3114,300,759USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2020-12-3116,630,632USD
At 2020-09-3014,616,848USD
At 2020-06-3011,788,691USD
At 2020-03-3110,655,821USD
At 2019-12-319,079,882USD
At 2019-09-30-3,058,300USD
At 2019-06-30-1,861,668USD
At 2019-03-31-2,507,864USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2020-12-315,412,785USD
At 2020-03-311,131,728USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2020-10-01 to 2020-12-312,012,133USD92
2020-04-01 to 2020-12-315,571,044USD275
2019-10-01 to 2019-12-31-1,860,680USD92
2019-04-01 to 2019-12-31-3,176,719USD275

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2020-04-01 to 2020-12-313,943,229USD275
2019-04-01 to 2019-12-31-587,684USD275

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2020-10-01 to 2020-12-316,046,582USD92
2020-04-01 to 2020-12-3120,985,218USD275
2019-10-01 to 2019-12-315,055,113USD92
2019-04-01 to 2019-12-3113,049,340USD275

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2020-04-01 to 2020-12-31415,910USD275
2019-04-01 to 2019-12-31188,719USD275

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2020-04-01 to 2020-12-31-77,879USD275
2019-04-01 to 2019-12-31-3,148USD275

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2020-12-31-148,475,366USD
At 2020-03-31-154,046,410USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2020-10-01 to 2020-12-311,009,176,752shares92
2020-04-01 to 2020-12-31921,339,333shares275
2019-10-01 to 2019-12-31829,394,203shares92
2019-04-01 to 2019-12-31828,466,951shares275

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2020-10-01 to 2020-12-311,009,176,752shares92
2020-04-01 to 2020-12-31921,339,333shares275
2019-10-01 to 2019-12-31829,394,203shares92
2019-04-01 to 2019-12-31828,466,951shares275

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2020-10-01 to 2020-12-310USD/shares92
2020-04-01 to 2020-12-310.01USD/shares275
2019-10-01 to 2019-12-310USD/shares92
2019-04-01 to 2019-12-310USD/shares275

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2020-10-01 to 2020-12-310USD/shares92
2020-04-01 to 2020-12-310.01USD/shares275
2019-10-01 to 2019-12-310USD/shares92
2019-04-01 to 2019-12-310USD/shares275

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2020-12-316,783,904USD
At 2020-03-317,227,648USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2020-10-01 to 2020-12-311,001,169USD92
2020-04-01 to 2020-12-313,172,026USD275
2019-10-01 to 2019-12-31691,195USD92
2019-04-01 to 2019-12-31-911,042USD275

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2020-12-3114,538,170USD
At 2020-03-3110,251,279USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2020-10-01 to 2020-12-3179,673USD92
2020-04-01 to 2020-12-31238,857USD275
2019-10-01 to 2019-12-3194,514USD92
2019-04-01 to 2019-12-31283,649USD275

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2020-12-317,242,350USD
At 2020-03-318,639,548USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2020-12-31700,905USD
At 2020-03-311,577,860USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2020-12-313,296,207USD
At 2020-03-314,106,846USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2020-10-01 to 2020-12-312,402,238USD92
2020-04-01 to 2020-12-316,829,171USD275
2019-10-01 to 2019-12-312,200,542USD92
2019-04-01 to 2019-12-316,430,464USD275

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2020-12-314,802,007USD
At 2020-03-314,142,472USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2020-10-01 to 2020-12-313,403,407USD92
2020-04-01 to 2020-12-3110,001,197USD275
2019-10-01 to 2019-12-312,891,737USD92
2019-04-01 to 2019-12-315,519,422USD275

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2020-10-01 to 2020-12-312,643,175USD92
2020-04-01 to 2020-12-3110,984,021USD275
2019-10-01 to 2019-12-312,163,376USD92
2019-04-01 to 2019-12-317,529,918USD275

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2020-10-01 to 2020-12-311,245,669USD92
2020-04-01 to 2020-12-313,337,287USD275
2019-10-01 to 2019-12-31986,832USD92
2019-04-01 to 2019-12-313,032,357USD275

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2020-12-311,009,176,752shares
At 2020-03-31840,404,367shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2020-12-315,817,790USD
At 2020-03-311,536,530USD
At 2019-12-312,273,655USD
At 2019-03-312,675,768USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2020-12-31212,385USD
At 2020-03-31363,282USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2020-12-31221,166USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2020-12-3118,618,089USD
At 2020-03-3118,184,982USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2020-12-3111,834,185USD
At 2020-03-3110,957,334USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2020-12-316,634,035USD
At 2020-03-316,634,035USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2020-12-31496,743USD
At 2020-03-31480,336USD

Other noncurrent liabilities

Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2020-12-3137,068USD
At 2020-03-3135,442USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2020-12-314,605,014USD
At 2020-03-314,821,132USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2020-12-311,027,171USD
At 2020-03-31870,233USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2020-10-01 to 2020-12-312,012,133USD92
2020-04-01 to 2020-12-314,627,137USD275
2019-10-01 to 2019-12-31-1,860,680USD92
2019-04-01 to 2019-12-31-3,174,719USD275

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2020-10-01 to 2020-12-312,012,133USD92
2020-07-01 to 2020-09-302,481,562USD92
2020-04-01 to 2020-06-301,077,349USD91
2019-10-01 to 2019-12-31-1,860,680USD92
2019-07-01 to 2019-09-30-1,595,741USD92
2019-04-01 to 2019-06-30279,702USD91

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2020-10-01 to 2020-12-312,012,133USD92
2020-04-01 to 2020-12-315,571,044USD275
2019-10-01 to 2019-12-31-1,860,680USD92
2019-04-01 to 2019-12-31-3,176,719USD275

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2020-10-01 to 2020-12-31826,019USD92
2020-04-01 to 2020-12-312,491,762USD275
2019-10-01 to 2019-12-31878,540USD92
2019-04-01 to 2019-12-312,358,588USD275

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2020-10-01 to 2020-12-31505,987USD92
2020-04-01 to 2020-12-31980,227USD275
2019-10-01 to 2019-12-31326,908USD92
2019-04-01 to 2019-12-31982,456USD275

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2020-04-01 to 2020-12-31990,861USD275
2019-04-01 to 2019-12-31993,086USD275

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2020-10-01 to 2020-12-311,010,964USD92
2020-04-01 to 2020-12-311,455,111USD275
2019-10-01 to 2019-12-31-2,551,875USD92
2019-04-01 to 2019-12-31-2,263,677USD275

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2020-04-01 to 2020-12-31239,940USD275
2019-04-01 to 2019-12-31168,560USD275

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2020-04-01 to 2020-12-3142,223USD275
2019-04-01 to 2019-12-31806,987USD275

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2020-04-01 to 2020-12-31-810,639USD275
2019-04-01 to 2019-12-311,243,518USD275

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2020-04-01 to 2020-12-31659,535USD275
2019-04-01 to 2019-12-31-705,322USD275

Inspect the source

Entity
Elite Pharmaceuticals, Inc. / CIK 0001053369
Captured
2026-09-20T05:17:33.154Z
SEC response SHA-256
b91e0331a01f96870ee44e841f605bd504e1bc784022b77f374cfe93dc363314

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001053369.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))